Cell manufacturing with GMP ancillary material solutions from BioLegend
End-to-end contract development and manufacturing services for tailor-made GMP ancillary material for cell therapy manufacturing.
High-quality ancillary materials for bioprocessing—meeting both functional and safety standards—are essential for the consistent and successful manufacturing of cell therapies destined for clinical use.
Building on decades of experience in biologics manufacturing for research applications, BioLegend has expanded its GMP capabilities to support the production of biological materials intended for use as ancillary and raw materials in cell therapy manufacturing.
In this session, their experts will present an overview of their comprehensive contract development and manufacturing services, highlight their GMP bioprocessing capabilities in alignment with relevant regulatory guidelines (e.g., USP <1043>), and share project examples demonstrating how their ancillary material solutions can help advance your novel cell therapy to the clinic.
What will you learn?
- Overview of BioLegend’s end-to-end contract development and manufacturing services for producing ancillary materials used in downstream cell therapy manufacturing
- Introduction to key regulatory guidelines for ancillary and raw materials in cell therapy manufacturing (e.g., USP <1043>, EP 5.2.12)
- Case studies showcasing prior projects to illustrate how our services can support the advancement of novel cell therapies toward regulatory approval and clinical application
Who this may interest?
- Process development scientists/engineers
- CDMO scientists/affiliates
- Cell therapy manufacturing and operations teams
- Quality control and regulatory affairs specialists
- Bioprocessing specialists
- CMC leads
Speaker
Kenta Yamamoto
Program Manager, Custom GMP Bioprocessing
BioLegend (CA, USA)
Kenta Yamamoto is the Program Manager of Custom GMP Bioprocessing at BioLegend/Revvity where he partners with customers to plan and oversee bioprocessing contract development and manufacturing service projects. He previously served as the Cell Analysis Product Manager at BioLegend and brings postdoctoral research experience in stem cell–derived natural killer cells for cancer immunotherapy.
This webinar was recorded on 23 September 2025.
In association with